Entering text into the input field will update the search result below

Genetron's CDx test Ayvakit enters priority review and approval process in China

  • Genetron Holdings (NASDAQ:GTH) announces that its Ayvakit (avapritinib) companion diagnostic (CDx) kit, developed in partnership with CStone Pharmaceuticals (OTCPK:CSPHF) has entered the priority review and approval process in China.
  • Shares down 3% premarket at $18.00.
  • During the process, the Center for Medical Device

Recommended For You

More Trending News

About GTH Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
GTH--
Genetron Holdings Limited